CorMedix Shares Gain After 1Q Preliminary Sales Beat Views

Dow Jones

04/08

By Katherine Hamilton

CorMedix shares rose after the company's preliminary first-quarter revenue figure came in above expectations.

Shares climbed 16.5% to $7.07 Tuesday. The stock is down 14.1% so far this year.

The Berkeley Heights, N.J., biopharmaceutical company recorded preliminary first-quarter revenue of $39 million, it said Tuesday. Analysts polled by FactSet were forecasting $32.3 million.

CorMedix also increased first-half guidance for sales to existing purchasing customers to between $62 million and $70 million.

The company said it received larger-than-expected orders during the final week of March. It also has more visibility into inventory levels on hand at some current purchasing customers, it said.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

April 08, 2025 10:14 ET (14:14 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2525681668"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2525681668\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2525681668?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-08 22:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2525681668","market":"sg","top_or_hot":-1,"title":"CorMedix Shares Gain After 1Q Preliminary Sales Beat Views","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  CorMedix shares rose after the company's preliminary first-quarter revenue figure came in above expectations. \n</p>\n<p>\n  Shares climbed 16.5% to $7.07 Tuesday. The stock is down 14.1% so far this year. \n</p>\n<p>\n  The Berkeley Heights, N.J., biopharmaceutical company recorded preliminary first-quarter revenue of $39 million, it said Tuesday. Analysts polled by FactSet were forecasting $32.3 million. \n</p>\n<p>\n  CorMedix also increased first-half guidance for sales to existing purchasing customers to between $62 million and $70 million. \n</p>\n<p>\n  The company said it received larger-than-expected orders during the final week of March. It also has more visibility into inventory levels on hand at some current purchasing customers, it said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 08, 2025 10:14 ET (14:14 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CorMedix Shares Gain After 1Q Preliminary Sales Beat Views</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorMedix Shares Gain After 1Q Preliminary Sales Beat Views\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-08 22:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  CorMedix shares rose after the company's preliminary first-quarter revenue figure came in above expectations. \n</p>\n<p>\n  Shares climbed 16.5% to $7.07 Tuesday. The stock is down 14.1% so far this year. \n</p>\n<p>\n  The Berkeley Heights, N.J., biopharmaceutical company recorded preliminary first-quarter revenue of $39 million, it said Tuesday. Analysts polled by FactSet were forecasting $32.3 million. \n</p>\n<p>\n  CorMedix also increased first-half guidance for sales to existing purchasing customers to between $62 million and $70 million. \n</p>\n<p>\n  The company said it received larger-than-expected orders during the final week of March. It also has more visibility into inventory levels on hand at some current purchasing customers, it said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 08, 2025 10:14 ET (14:14 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRMD","symbol_name":"CorMedix Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2525681668","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2525681668","pubTimestamp":1744121640,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"CorMedix shares rose after the company's preliminary first-quarter revenue figure came in above expectations.Shares climbed 16.5% to $7.07 Tuesday. The stock is down 14.1% so far this year.The Berkeley Heights, N.J., biopharmaceutical company recorded preliminary first-quarter revenue of $39 million, it said Tuesday. Analysts polled by FactSet were forecasting $32.3 million.CorMedix also increased first-half guidance for sales to existing purchasing customers to between $62 million and $70 million.The company said it received larger-than-expected orders during the final week of March. It also has more visibility into inventory levels on hand at some current purchasing customers, it said.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CRMD":"CorMedix Inc."},"translate_title":"第一季度初步销售额超出预期后CorMedix股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRMD":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  CorMedix shares rose after the company's preliminary first-quarter revenue figure came in above expectations. \n\n\n  Shares climbed 16.5% to $7.07 Tuesday. The stock is down 14.1% so far this year. \n\n\n  The Berkeley Heights, N.J., biopharmaceutical company recorded preliminary first-quarter revenue of $39 million, it said Tuesday. Analysts polled by FactSet were forecasting $32.3 million. \n\n\n  CorMedix also increased first-half guidance for sales to existing purchasing customers to between $62 million and $70 million. \n\n\n  The company said it received larger-than-expected orders during the final week of March. It also has more visibility into inventory levels on hand at some current purchasing customers, it said. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2025 10:14 ET (14:14 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}